company background image
BGBIO logo

BerGenBio OB:BGBIO Stock Report

Last Price

NOK 1.70

Market Cap

NOK 71.9m

7D

8.3%

1Y

-91.2%

Updated

31 Mar, 2025

Data

Company Financials +

BerGenBio ASA

OB:BGBIO Stock Report

Market Cap: NOK 71.9m

BGBIO Stock Overview

A clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. More details

BGBIO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Earnings have grown 6.8% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the Norwegian market

Does not have a meaningful market cap (NOK66M)

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (NOK848K)

+ 2 more risks

BerGenBio ASA Competitors

PCI Biotech Holding

OB:PCIB

NOK 51.5m

Arctic Bioscience

OB:ABS

NOK 150.9m

EXACT Therapeutics

OB:EXTX

NOK 201.2m

Lytix Biopharma

OB:LYTIX

NOK 341.3m

Price History & Performance

Summary of share price highs, lows and changes for BerGenBio
Historical stock prices
Current Share PriceNOK 1.70
52 Week HighNOK 20.00
52 Week LowNOK 1.45
Beta1.43
1 Month Change-2.86%
3 Month Change-79.22%
1 Year Change-91.24%
3 Year Change-99.92%
5 Year Change-99.89%
Change since IPO-99.93%

Recent News & Updates

We Think BerGenBio (OB:BGBIO) Needs To Drive Business Growth Carefully

Jan 06
We Think BerGenBio (OB:BGBIO) Needs To Drive Business Growth Carefully

Recent updates

We Think BerGenBio (OB:BGBIO) Needs To Drive Business Growth Carefully

Jan 06
We Think BerGenBio (OB:BGBIO) Needs To Drive Business Growth Carefully

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Sep 21
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Jun 02
Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

Dec 07
Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Aug 24
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Feb 06
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Sep 26
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Jun 11
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Feb 17
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

Sep 21
We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

Mar 13
It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Feb 11
We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Dec 21
What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Shareholder Returns

BGBIONO BiotechsNO Market
7D8.3%-0.2%-0.8%
1Y-91.2%-55.6%5.6%

Return vs Industry: BGBIO underperformed the Norwegian Biotechs industry which returned -55.6% over the past year.

Return vs Market: BGBIO underperformed the Norwegian Market which returned 5.6% over the past year.

Price Volatility

Is BGBIO's price volatile compared to industry and market?
BGBIO volatility
BGBIO Average Weekly Movement27.6%
Biotechs Industry Average Movement9.6%
Market Average Movement5.3%
10% most volatile stocks in NO Market13.1%
10% least volatile stocks in NO Market2.9%

Stable Share Price: BGBIO's share price has been volatile over the past 3 months compared to the Norwegian market.

Volatility Over Time: BGBIO's weekly volatility has increased from 18% to 27% over the past year.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

About the Company

FoundedEmployeesCEOWebsite
200715Olav Hellebowww.bergenbio.com

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors.

BerGenBio ASA Fundamentals Summary

How do BerGenBio's earnings and revenue compare to its market cap?
BGBIO fundamental statistics
Market capNOK 71.92m
Earnings (TTM)-NOK 139.28m
Revenue (TTM)NOK 848.00k

78.4x

P/S Ratio

-0.5x

P/E Ratio

Is BGBIO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BGBIO income statement (TTM)
RevenueNOK 848.00k
Cost of RevenueNOK 0
Gross ProfitNOK 848.00k
Other ExpensesNOK 140.13m
Earnings-NOK 139.28m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 29, 2025

Earnings per share (EPS)-3.56
Gross Margin100.00%
Net Profit Margin-16,424.76%
Debt/Equity Ratio0.7%

How did BGBIO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/31 19:19
End of Day Share Price 2025/03/31 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BerGenBio ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ulrik TrattnerCarnegie Investment Bank AB
Geir HolomDNB Markets
Sean ConroyEdison Investment Research